Longevity.Technology: Proteomics, the study of proteins in the body, has long been touted for its potential to help develop more effective ways to diagnose, treat and prevent diseases, but the field to date has largely focused on the discovery of protein biomarkers. Range Bio is founded on the belief that a significant impact on human health can only be realized if biomarker discovery is complemented by scalable, targeted quantification of proteins. We caught up with the company’s CEO Dr Brandon Wilson and CTO Dr Nicolo Maganzini to find out more.

With the Potential to Revolutionize Personalized Health, Range Biotechnologies Receives $5.2 Million in Seed Funding Led by TechBio-Focused ARTIS Ventures. Range Bio seeks to enable better diagnostics and faster drug development by unlocking translational proteomics